All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation
The Multiple Myeloma Hub are pleased to present a series of expert interviews from the 61st American Society of Hematology (ASH) meeting in Orlando, US. In this video, Mark Bustoros, Dana-Farber Cancer Institute, Boston, US, answers the question: What are the latest advances in treating high-risk smoldering myeloma?
Dr Bustoros presents the results from a phase II trial of ixazomib, lenalidomide and dexamethasone in patients with high-risk smoldering myeloma. 48/53 patients were evaluable for response, with nearly 50% achieving a complete response (CR) or very good partial response (VGPR). 70% of patients who achieved CR were also minimal residual disease (MRD) negative. It was also a well-tolerated regimen, administered orally.
What are the latest advances in treating high-risk smoldering myeloma?
How should we treat smoldering myeloma?
At ASH 2019, Irene Ghobrial, Dana-Farber Cancer Institute, Boston, US, answers the question: How should we treat smoldering myeloma?
Subscribe to get the best content related to multiple myeloma delivered to your inbox